Pharma
Panelists at this morning's DTx West discuss how governments worldwide are looking at digital therapeutics.
The randomized controlled trial of the jointly-developed digital therapeutics will be conducted using Verily's Project Baseline and enroll up to 540 patients.
The partnership will be looking to use AliveCor's Kardia-K AI, which is designed to measure a patient's potassium levels.
The solution uses AI and machine learning to improve adherence.
MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.
Also: Kaiser Permanente doubles down on the cloud with Accenture and Microsoft; Boehringer Ingelheim arms its reps with BreezoMeter's air quality data.
Machine learning applications are proliferating and improving, and this month we'll explore the many ways they're being put to work.
Flare Capital's Alexandra Mullin and Ian Chiang outline COVID-19's impact on the worsening opioid crisis and how the digital opioid use disorder space is likely to develop over the coming years.
Also: Blood glucose monitoring could be coming to next-gen consumer smartwatches; new incubator looking for disruptive health tech startups.
Asset Management Ventures' Skip Fleshman outlines COVID-19's impact on clinical trials and the resulting leap toward tech-enabled decentralized trials.